Page last updated: 2024-08-22

tetrapentylammonium and pazopanib

tetrapentylammonium has been researched along with pazopanib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abdelwahed, R; Arakawa, H; Ellawatty, WEA; Fujita, KI; Ishida, H; Kato, Y; Masuo, Y; Nakamichi, N; Sasaki, Y; Yamazaki, E	1

Other Studies

1 other study(ies) available for tetrapentylammonium and pazopanib

Article	Year
Organic Cation Transporter 1 Is Responsible for Hepatocellular Uptake of the Tyrosine Kinase Inhibitor Pazopanib. Drug metabolism and disposition: the biological fate of chemicals, 2018, Volume: 46, Issue:1 Topics: Administration, Intravenous; Animals; Cyclosporine; HEK293 Cells; Hepatocytes; Humans; Indazoles; Inhibitory Concentration 50; Liver; Male; Metformin; Mice; Mice, Inbred ICR; Octamer Transcription Factor-1; Protein Kinase Inhibitors; Pyrimidines; Quaternary Ammonium Compounds; Sulfonamides; Tissue Distribution; Transfection	2018

Article

Year

Organic Cation Transporter 1 Is Responsible for Hepatocellular Uptake of the Tyrosine Kinase Inhibitor Pazopanib.

Drug metabolism and disposition: the biological fate of chemicals, 2018, Volume: 46, Issue:1

Topics: Administration, Intravenous; Animals; Cyclosporine; HEK293 Cells; Hepatocytes; Humans; Indazoles; Inhibitory Concentration 50; Liver; Male; Metformin; Mice; Mice, Inbred ICR; Octamer Transcription Factor-1; Protein Kinase Inhibitors; Pyrimidines; Quaternary Ammonium Compounds; Sulfonamides; Tissue Distribution; Transfection

2018